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Abstract: Infections caused by Aspergillus spp. remain associated with high morbidity and mortality.
While mold-active antifungal prophylaxis has led to a decrease of occurrence of invasive aspergillosis
(IA) in those patients most at risk for infection, breakthrough IA does occur and remains difficult
to diagnose due to low sensitivities of mycological tests for IA. IA is also increasingly observed in
other non-neutropenic patient groups, where clinical presentation is atypical and diagnosis remains
challenging. Early and targeted systemic antifungal treatment remains the most important predictive
factor for a successful outcome in immunocompromised individuals. Recent guidelines recommend
voriconazole and/or isavuconazole for the primary treatment of IA, with liposomal amphotericin B
being the first alternative, and posaconazole, as well as echinocandins, primarily recommended for
salvage treatment. Few studies have evaluated treatment options for chronic pulmonary aspergillosis
(CPA), where long-term oral itraconazole or voriconazole remain the treatment of choice.
Keywords: Aspergillus; posaconazole; amphotericin; isavuconazole; voriconazole; itraconzole;
invasive aspergillosis; chronic pulmonary aspergillosis; diagnosis; interleukin 8
1. Introduction
Aspergillus spp. are filamentous, environmental fungi that cause a wide spectrum of infections in
humans, including hypersensitivity reactions, chronic pulmonary infections, and acute life-threatening
infections, the latter occurring primarily in immunocompromised individuals [1–4]. Of over 250 species
of Aspergillus, fewer than 40 are known to cause infections in humans [5], and of these, Aspergillus
fumigatus is the most common cause of infections in humans and is the most common cause of serious,
invasive disease.
The 2017 global estimates indicated that more than 3,000,000 cases of chronic pulmonary
aspergillosis (CPA), and ≈250,000 cases of invasive aspergillosis (IA) occur annually [6].
Prior population-based estimates of invasive aspergillosis (IA) in the 1990s suggest an annual incidence
rate of 1 to 2 cases of aspergillosis per 100,000 population [7], although given the increasing number
of solid organ transplant (SOT) and stem cell transplant (SCT) recipients, as well as the increased
use of immunosuppression, this study likely underestimates the current incidence of IA. In high-risk
populations, such as SCT recipients, the 12-month incidence of invasive fungal infections (IFIs) is 3.4%,
with IA causing around half of those infections [3]. In SOT recipients, the annual incidence of IA was
0.65% in one large study [8].
IA most commonly involves the lungs, where individuals present with signs and symptoms
of pneumonia including fever, chest pain, and hemoptysis, although other organ systems may be
involved. Diagnostic modalities are evolving, but Aspergillus infections are most commonly diagnosed
by culture, histopathology, or by galactomannan antigen detection in blood or bronchoalveolar lavage
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fluid (BALF). The optimal management of infections from IA includes prevention, early diagnosis,
early initiation of antifungal therapy, reduction in immunosuppressive therapy if possible, and in
some cases, surgery. Amphotericin B was an early treatment option for IA and its newer lipid-based
formulations are still used in some instances, although newer options including voriconazole and
isavuconazole are now often preferred.
CPA is progressing more slowly than IA and affects patients with pre-existing pulmonary
pathology, such as active or previous tuberculosis and non-tuberculosis mycobacterial infection,
previous surgery for lung cancer, chronic obstructive pulmonary disease (COPD), or sarcoidosis,
although the later may also be at risk for IA due to concomitant immunosuppressive treatment [1,9].
2. Clinical Manifestations and Diagnosis
IA is primarily found in the lungs but may disseminate to other organs. Signs and symptoms
depend on which organs are affected, and may include cough, hemoptysis, dyspnea, chest pain,
skin lesions, or neurological symptoms. Importantly, pathogenesis of IA and associated signs and
symptoms, as well as radiological presentation and diagnostic test performance, differs markedly
between patients with neutropenia (i.e., primarily angioinvasive growth) and non-neutropenic patients
(i.e., primarily airway invasive growth) [10,11]. While fever is present in >95% of neutropenic patients
with IA, it is present in only 50–70% of non-neutropenic patients with IA [12], and cough and chest
pain may be less frequently observed in non-neutropenic patients [12]. Radiological presentation in
chest computed tomography (CT) differs by neutrophil count, with “typical” signs of IA including the
halo sign or air crescent sign being frequently observed in neutropenic patients, while non-specific
infiltrates or consolidations are most frequently observed in non-neutropenic patients [13,14]. Strikingly,
“typical” radiologic signs, as defined by consensus definitions of IA, are present in only 30–50% of
non-neutropenic proven IA cases [13]. As a consequence, IA remains difficult to diagnose, particularly
in non-neutropenic patients where clinical presentation and radiological signs are mostly atypical.
Therefore, diagnosis of IA is often delayed, and IA remains associated with high mortality rates of
around 30–40% [15].
Due to the absence of a single “gold standard” test for the diagnosis of IA, different mycological
assays are employed and combined with clinical, radiological, and histological methods. Mycological
diagnostic approaches for IA include fungal culture from BALF and biopsies; immunodetection of
the cell wall component galactomannan (GM) in serum, BALF, and urine; detection of the cell wall
component 1,3-β-D-glucan (BDG) via factor G activation in serum; detection of Aspergillus-specific
siderophores in BALF or urine; detection of an Aspergillus-specific cell wall protein via a lateral flow
device test (LFD); and detection of Aspergillus-specific DNA via PCR in blood and BALF [16–33].
The most commonly used non-culture-based approach for IA diagnosis is GM detection in serum and
BALF. In contrast to BALF GM detection, performance of serum GM is heavily influenced by neutrophil
status of the host with sensitivities over 60–70% in neutropenic patients with angioinvasive growth but
sensitivities are often <20% in non-neutropenic patients with airway invasive growth [34–36]. Another
factor that reduces sensitivities of all diagnostic tests for IA, including culture, GM, PCR, and LFD is
ongoing mold-active antifungal prophylaxis or treatment [37–40]. Given the reduced sensitivities of
all available diagnostic tests in patients receiving mold-active antifungals, combination of multiple
diagnostic tests and biomarkers from BALF and blood is the currently recommended approach, and has
been shown to be associated with a significant increase of sensitivities, while specificities were only
reduced slightly [19,20,23,30,32,41–43]. The most promising combinations include PCR and/or the
Aspergillus-specific LFD and/or GM from BALF with serum GM and/or very high levels of serum
interleukin 8, which has recently been shown to be highly sensitive and specific when combined with
BALF LFD or PCR [19,22,23,26,27,30,32,33].
CPA is characterized by slowly progressive destruction of lung parenchyma, in the form of
single of multiple cavities, nodules, infiltrates, or fibrosis, with or without an aspergilloma [2]. Due to
the nonspecific and indolent presentation, diagnosis may be delayed or missed, resulting in severe
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morbidity. Diagnostic criteria include presence of respiratory and/or constitutional symptoms for at
least 3 months, suggestive abnormalities on imaging, and serological or microbiological evidence of
Aspergillus [44]. For mycological evidence, Aspergillus specific IgG has a central role, while biomarkers
and tests for invasive growth, including GM, are mostly negative [44,45].
3. Treatment of Aspergillus Infections
3.1. Treatment of Invasive Aspergillosis
Early systemic antifungal treatment is of primary importance for survival against IA, while surgery
plays an important role mainly in rarer disease manifestations of invasive disease including, e.g.,
sinusitis and osteomyelitis. Pharmacokinetic characteristics of broad-spectrum triazoles, liposomal
amphotericin B, and echinocandins are reviewed in Table 1. The indications for surgery for IA have
been extensively reviewed before [46]. The same applies to CNS infections and endophthalmitis where
drug penetration considerations are particularly important (see also Table 1) [47].
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Table 1. Pharmacokinetic Characteristics of Broad-Spectrum Triazoles, Liposomal Amphotericin B, and Echinocandins [48–52].
Voriconazole Isavuconazole Posaconazole LiposomalAmphotericin B Caspofungin Anidulafungin
Dosage
IV: 6 mg/kg Q12 × 24 h,
4 mg/kg Q12 starting Day 2
PO: 200 mg Q12 h
IV: 200 mg Q8 h × 48 h, 200 mg daily
starting Day 3
PO: 200 mg Q8 h for 48 h, 200 mg daily
starting Day 3
IV: 300 mg Q12 × 24 h, 300 mg daily
starting Day 2
Delayed-release: 300 mg Q12 ×24 h,
300 mg daily starting Day 2
Oral suspension: 200 mg TID
IV: 3 mg/kg/day 70 mg daily on Day 1,50 mg daily starting Day 2
200 mg daily on Day
1, 100 mg starting
Day 2
Formulation PO, IV PO, IV PO, IV IV IV IV
Half-Life (h) 6 110–115 27–35 7–10 9–11 24–26
Bioavailability Oral, 96% Oral, 98% Tablet: 54%Oral suspension:Variable Oral, 9% Oral, <5% Oral, <5%
Linear PK No High IV: NoSuspension/Tablet: High Yes, doses 1–3 mg/kg;No at higher doses Yes (Animal Model) Yes (Animal Model)
Renal Excretion 2% <1% <1% 4.5% 41% <1%
CNS
Penetration High High (Animal Model) Low High (Animal Model) Low (Animal Model) Low (Animal Model)
Metabolism CYP2C19, CYP2C9, CYP3A4 CYP3A4/5 UGT Unknown Hydrolysis andN-acetylation
Spontaneous
biotransformation
into inactive peptide
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3.1.1. Amphotericin B
Intravenous (IV) amphotericin B, a polyene, binds to ergosterol in fungal membranes
forming pores and leading to cell death. It is used to treat a number of fungal infections,
including IA, mucormycosis, cryptococcal meningitis, and invasive candidiasis. Investigation of
liposomal amphotericin B (L-AmB) has shown a positive correlation between in-vitro susceptibility
testing and positive clinical outcomes in patients with IA. In a study of 29 patients with IA
following SCT, all six patients with a mean inhibitory concentration (MIC) of <2 mg/L to
L-AmB survived, while 22/23 patients with isolates with an MIC ≥2 mg/L died [53]. Another
study using a pharmacokinetic-pharmacodynamic (PK-PD) model simulating free amphotericin B
serum concentrations found the estimated breakpoints for susceptibility, intermediate susceptibility,
and resistance for A. fumigatus to be ≤0.5, 1, and ≥2, respectively [54]. Overall, L-AmB remains
sensitive against most Aspergillus spp., although increasing rates of elevated MICs >2 have recently
been reported for Aspergillus fumigatus (>40% of isolates MICs >2), and Apergillus flavus (>80% of
isolates) [55]. Aspergillus terreus shows intrinsic resistance [56].
In a prospective, randomized, multicenter trial of patients with either hematologic malignancy
or status post SCT, patients were given either L-AmB at 1 mg/kg or L-AmB at 4 mg/kg daily. Of 87
evaluable patients, there was no difference in radiologic response, 6-month survival rates, or deaths
between the two groups. The six-month survival rate was around 40% in both groups, with about 50%
of those deaths thought to be related to IA [57]. Another multi-center randomized trial investigated
L-AmB at either 3 mg/kd/day or 10 mg/kg/day for 14 days followed by 3 mg/kg per day. The vast
majority of patients in this study had underlying hematologic malignancy and IA accounted for 97%
of invasive fungal infections. There was no difference in clinical response or survival between the
two groups, with clinical response in 50% of patients and 12-week survival of 72% in the 3 mg/kg
per day cohort [58]. In a pooled analysis of published trials investigating L-AmB for the treatment of
IA and other filamentous fungal infections in immunocompromised individuals, favorable response
rates were observed in about 51% of cases of probable or proven invasive fungal infections [59].
While L-AmB remains an important agent for treatment of IA and other invasive mold infections [60],
high rates of toxicity and side effects from L-AmB, including infusion-related reactions, phlebitis
during infusion, gastrointestinal side effects such as diarrhea, nausea, and vomiting, transaminitis,
electrolyte derangements, and nephrotoxicity have led to the investigation of other, better tolerated
agents [61].
3.1.2. Azoles
Broad-spectrum triazoles inhibit ergosterol synthesis in the membrane sterol of fungi leading to
cell death. Several of the newer-generation triazoles, particularly voriconazole and isavuconazole,
are appealing alternatives to the use of L-AmB. While azole resistant clinical Aspergillus isolates
have been reported from many parts of the world, resistance rates remain low in most settings,
not influencing primary choice of antifungal therapy [62]. Pharmacokinetics of a broad spectrum
differ significantly, and intra- and interpatient variability of plasma levels, but also variability in
intracellular concentrations remains an issue [63]. Therapeutic drug monitoring (TDM) may be
required to achieve efficacy and also to avoid toxicity in particular for voriconazole in treatment and
prophylactic settings [64–66], but also for posaconazole oral suspension (efficacy only) [67–69], which is
associated with significantly lower posaconazole plasma concentrations when compared to tablet or
IV formulations [70], while there are currently no recommendations of TDM for isavuconazole [63,71].
Voriconazole, available in tablet, IV, and suspension formulation, is approved for the treatment
of IA, Candida infections, scedosporiosis, and furasiosis. A prospective randomized trial in patients
with underlying hematologic disease and IA investigated 144 patients randomized to receive IV
voriconazole and 133 patients randomized to receive IV amphotericin B deoxycholate. The primary
outcome was partial or complete response to therapy. At twelve weeks, 52.8% of patients met the
primary outcome in the voriconazole group (a complete response of 20.8% and a partial response of
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31.9%) versus 31.6% in the amphotericin group (a complete response of 16.5% and a partial response of
15.0%), a statistically significant difference. At 12 weeks, the survival rate was 70.8% in the voriconazole
group versus 57.9% in the amphotericin group, which again was statistically significant. In addition,
there were fewer drug-related adverse events in the voriconazole group, although side effects to
treatment, such as blurry vision and photophobia, were common [72]
Isavuconazole, available in capsule and IV formulation, is another triazole preferred for the
treatment of IA [63,73–75]. In the large randomized SECURE trial, 527 patients with invasive mold
infection were randomized to receive either IV isavuconazole followed by IV or oral (PO) isavuconazole
versus IV voriconazole followed by IV or PO voriconazole. The majority of patients in both groups had
underlying hematologic malignancy (82% in the isavuconazole group versus 86% in the voriconazole
group). The primary endpoint was all-cause mortality at 6 weeks and Aspergillus spp were the cause of
infection in 30% of patients in both groups. At 6 weeks, 19% of patients in the isavuconazole group
died compared to 20% in the voriconazole group, a difference that did not meet statistical significance.
Drug-related adverse events were significantly higher in the voriconazole group compared to the
isavuconazole group (60% versus 42%, p < 0.001), and permanent drug discontinuation was lower in
the isavuconazole group compared to the voriconazole group (8% versus 14%) [76].
A number of studies have suggested that posaconazole, available in delayed-release tablets, oral
suspension, and IV formulation, may be an option to treat refractory IA [77]. An open-labeled trial
investigated the use of posaconazole as a salvage therapy for the treatment of IA in patients that
were refractory or intolerant to other treatment, of which 80% of patients had underlying hematologic
malignancy. Of 107 patients who received posaconazole oral suspension, 42% had a treatment response
compared to 26% of the 86 external control patients (p = 0.006) [78]. In another prospective trial of
patients with refractory IA, 53 patients received posaconazole given orally or via an enteral feeding tube,
52 received lipid formulation of amphotericin B (LPD/AMB), and 38 patients received a combination
of caspofungin plus LPD/AMB. The primary outcome was clinical improvement or resolution at
12 weeks and over 90% of patients had underlying hematologic malignancy. The primary outcome
was met in 40% of patients in the posaconazole group, 8% in the LPD/AMB group, and 11% in the
combination group (p < 0.002). At 12 months, 40% of patients died in the posaconazole group compared
to 65% in the LPD/AMB group and 68% in the combination group (p < 0.008) [79].
3.1.3. Echinocandins
The echinocandins, which inhibit β-1,3-glucan synthesis in the cell wall of fungi, have also been
investigated for the treatment of IA. In an open-labeled, non-randomized, single-arm study, patients
with IA following SCT were given at least 15 days of IV caspofungin (a median duration of 24 days).
The primary endpoint was partial or complete clinical response. Enrollment was stopped early due
to slow enrollment and the study was under-powered. At 12 weeks, 8 patients (33%) had complete
or partial response to therapy and survival at 6 and 12 weeks was 79% and 50%, respectively [80].
In another open-label, non-randomized, single-arm study, patients with underlying hematologic
malignancy or following SCT were given at least 15 days of caspofungin (a median duration of 27
days). The primary endpoint was partial or complete clinical response. At the end of treatment 1
patient (1/61) had a complete response to treatment and 19 patients (19/61) had a partial response.
At 6 and 12 weeks the survival rate was 66% and 53%, respectively. Patients were not followed
beyond 12 weeks [81]. Lastly, another study looked at caspofungin for the treatment of refractory IA
and compared treatment responses to a historical cohort. The majority of patients had underlying
hematologic disease. Of 83 patients who received caspofungin, 45% experienced a complete or partial
clinical response to treatment, compared to a 16% response rate in the historical cohort, of which the
majority received amphotericin B with or without itraconazole [82].
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3.1.4. Combination Therapy
In a large randomized, double-blind, placebo-controlled multicenter trial, 454 patients with
hematological malignancies and suspected or documented IA were randomly assigned to primary
treatment with voriconazole and anidulafungin or voriconazole and placebo. Primary analysis was
done in the modified intention-to-treat population of 277 patients in whom IA was confirmed.
Mortality rates at 6 weeks were 19.3% for combination therapy and 27.5% for monotherapy (difference,
−8.2 percentage points [95% CI, −19.0 to 1.5]; p = 0.087). In a post hoc analysis of 218 patients who had
IA diagnosis established by radiographic findings and galactomannan positivity, 6-week mortality was
lower in combination therapy than monotherapy (15.7% vs. 27.3%; difference, −11.5 percentage points
[CI, −22.7 to −0.4]; p = 0.037) [83]. While the study was insufficiently powered to detect a difference in
the main analysis, results indicate that combination therapy may be associated with better survival [83].
A multinational, open-label, non-comparative study investigated IV micafungin, alone or in
combination with other agents, for the treatment of IA. The primary outcome was partial or complete
clinical response. Of 225 patients who met inclusion criteria, the majority were SCT recipients or
had an underlying hematologic malignancy. Of those who received micafungin as primary therapy,
17/29 received combination therapy, with 2/17 experiencing a complete response to treatment and
3/17 a partial response (total response of 29%); 12/29 received monotherapy with micafungin with
0% experiencing a complete response and 6/12 experienced a partial response (a total response of
50%). Of those who received micafungin as salvage therapy, 174/196 received combination therapy
with 13/174 experiencing a complete response and 47/174 a partial response (a total response of
34.5%); 22/196 received micafungin monotherapy with 3/22 experiencing a complete response and
6/22 a partial response (a total response of 41%) [84]. An open-label, non-comparative study of SCT
recipients investigated micafungin alone or in combination with other agents for the treatment of IA.
Most patients (89%) had refractory IA that did not respond to initial first-line therapy. The primary
endpoint was response to therapy. Of 98 patients, 8 (8%) received micafungin monotherapy with
a treatment response rate of 38% (3/8). Of 90 patients (92%) who were treated with combination
therapy, the treatment response rate was 24% (22/90), with all but one of those treatment responses
being in patients with refractory IA [85].
Another study investigated caspofungin in combination with other agents for the treatment of
refractory IA. Of 53 patients, 30% (16/53) received caspofungin plus amphotericin B and 70% (37/53)
received caspofungin plus a triazole. Partial or complete resolution at the end of therapy and at Day
84 was 55% (29/53) and 49% (25/51), respectively. Survival at Day 84 was 55% [86]. Lastly, another
study looked at voriconazole plus caspofungin for the primary treatment of IA in SOT recipients and
compared outcomes to a historical cohort of SCT recipients who received LPD/AMB. At 90 days,
survival was 67.5% (27/40) in the combination therapy group versus 51% (24/47) in the historical
control group (p = 0.117) [87].
3.1.5. Guideline Recommendations
Current recommendations are summarized in Table 2. The Infectious Diseases Society of America
(IDSA) 2016 guidelines recommend voriconazole as first-line treatment for IA (AI recommendation) with
liposomal amphotericin B and isavuconazole as alternative options (AII recommendation). L-AmB is
an option for salvage therapy (AII recommendation) [88]. The more recently updated guidelines of
the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and the European
Confederation of Medical Mycology (ECMM), as well as the guidelines of the European Conference on
Infections in Leukemia (ECIL-6), both recommend voriconazole and isavuconazole as the preferred
agents for the treatment of IA in patients with underlying hematologic malignancy (AI—AII
recommendation and A1 recommendation, respectively). The ESCMID/ECMM 2017 and ECIL-6
recommend L-AmB as a second-line option (BII and BI recommendation, respectively) 1]. While the
IDSA does not recommend primary therapy with an echinocandin (AII), ESCMID/ECMM and ECIL-6
only marginally recommend primary treatment with an echinocandin (CII recommendations).
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Table 2. Recommendations for the Treatment of Invasive Pulmonary Aspergillosis.
Targeted Treatment of Invasive Pulmonary Aspergillosis in Hematologic Malignancy
Voriconazole Isavuconazole Itraconazole Liposomal Amphotericin B Echinocandins
ECIL-6 (61) AI AI CIII BI CII
ESCMID (60) AI-AII AI-AII CII-CIII BII CII-CIII
IDSA (83) AI AII - AII AII (not recommended)
Salvage Treatment for Invasive Pulmonary Aspergillosis in Hematologic Malignancy
Voriconazole Isavuconazole Itraconazole Liposomal Amphotericin B Posaconazole
ECIL-6 (61) BII BII CIII BII BII
ESCMID (60) AII AII CII-DIII BII BII
IDSA (83) - - AII AII AII
Combination Treatment for Invasive Pulmonary Aspergillosis in Hematologic Malignancy
Voriconazole + Echinocandin Other combinations
ECIL-6 (61) CI CIII
ESCMID (60) CI-CII DIII
IDSA (83) CII CII
Targeted Treatment of Chronic Pulmonary Aspergillosis
Voriconazole Isavuconazole Itraconazole Liposomal Amphotericin B Posaconazole
ECIL-6 (61) - - - - -
ESCMID (60) AII - AII - BII
IDSA (83) - - Preferred - -
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The IDSA gives combination treatment with voriconazole and an echinocandin a weak
recommendation, offering consideration for this approach in select patients (CII recommendation).
In line, ESCMID/ECMM 2017 and ECIL-6 both only marginally recommend combination antifungal
therapy with voriconazole plus an echinocandin for the primary treatment of IA (CI recommendation).
Posaconazole is given a BII grade by both the ESCMID/ECMM 2017 and ECIL-6 and is
recommended by the IDSA for use as a salvage therapy for IA (AII recommendation). In addition,
the ESCMID/ECMM recommends voriconazole as a first-line treatment of IA in patients without
hematologic malignancies (AIII recommendation). The IDSA recommends that antifungal therapy be
continued for a minimum of 6–12 weeks, with duration based on factors such as severity of infection,
duration of immunosuppression, and response to therapy. The ESCMID/ECMM recommends
treatment duration be based primarily on treatment response and immune reconstitution.
While currently available guidelines are targeted towards a small number of high-resource countries,
they mostly fail to provide guidance for low- and middle-income countries (LMICs). This will be
changed by the “One World–One Guideline” initiative, which has been spearheaded by the European
Confederation of Medical Mycology and has the goal to unify the medical mycology community,
by creating guidelines that are applicable worldwide including low- and middle-income countries [71].
3.1.6. Azole Resistance in Aspergillus Fumigatus
Although voriconazole and isavuconazole are the first-line agents for the treatment of IA,
resistance to these agents is emerging [89]. A single-center study in Brazil investigated susceptibility
profiles for Aspergillus isolates, of which A. fumigatus represented 74% of the 228 isolates. Nine patients
showed high MIC values to at least one azole, although none showed complete resistance. Of additional
concern, 43% of A. fumigatus isolates had an MIC >2 mg/L to amphotericin B, an important option
for treatment of refractory IA [56]. In a 2016 nationwide survey of Dutch Hematology Centers,
of 784 patients in which A. fumigatus was isolated, 101 isolates (12.9%) showed resistance to triazoles,
an increase from 10.7% of isolates in 2015 and 7.2% of isolates in 2014. Among individual Hematology
Centers, resistance ranged from 9.5% to 20.5%. This increasing resistance to triazoles is thought to
be due to the environmental use of azole fungicides. Because of high local resistance to triazoles in
one Dutch Hematology Center, L-AmB is frequently used as first-line therapy for IA [90]. Another
Dutch cohort study found that triazole resistance was found in 23/144 (16%) of patients with
influenza-associated IA, and that the detection of resistance to voriconazole was highly associated
with treatment failure [91]. Thus, there is a clear need for continued vigilance for triazole-resistant
strains of A. fumigatus.
3.1.7. New Agents to Treat Invasive Aspergillosis
While there has been substantial improvement in treatment of IA, associated with decreasing
mortality rates, more targeted methods may help to further decrease morbidity and mortality.
There are a number of promising new therapies under development for the treatment of IA. A novel
echinocandin, Biafungin (CD101), is currently under investigation in pre-clinical studies and showed
early promise in mouse models as a once-weekly dosing option for the prevention and treatment
of some IFIs, including IA [92]. Other agents are under investigation in clinical trials, some with
novel mechanisms of action. E1210 (Eisai Company, Tokyo, Japan) is investigating a novel agent
that targets the glycosylphosphatidylinositol (GP1) protein in the cell wall leading to the arrest
of fungal growth. E1210 was promising in pre-clinical studies with in vitro activity against most
yeast and molds including A. fumigatus and is entering phase I clinical trials [93]. F901318 (FTG
Ltd., Cheshire, United Kingdom) targets pyrimidine biosynthesis and has shown in vitro activity
against triazole-resistant molds such as A. fumigatus, Scedosporium spp., and Fusarium spp. in Phase I
study [94]. Phase II studies are currently ongoing. ASP2397 (Vical Inc., San Diego, CA, USA) is a novel
agent that inhibits aluminum iron chelation and has shown promise in Phase I clinical trials against
Aspergillus spp. [95].
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3.2. Treatment of Chronic Pulmonary Aspergillosis
In the only randomized-controlled trial of azole therapy (n = 17) versus supportive care (n = 14)
there was a significant benefit from a six-month course of itraconazole 400 mg daily [96]. Consequently,
triazoles including itraconazole and voriconazole are the treatment of choice for CPA, with AII
recommendation in the guideline published by the ESCMID, the European Respiratory Society (ERS),
and the ECMM and a strong recommendation in guideline published by the IDSA [44,88]. Posaconazole
(BII) can be used as an alternative [44].
4. Conclusions
Infections caused by Aspergillus spp. remain associated with high morbidity and mortality. While
mold-active antifungal prophylaxis has led to a decrease of occurrence of IA in those patients most
at risk for infection, IA is increasingly observed in other non-neutropenic patient groups, including
critically-ill patients with influenza, patients with caspase recruitment domain family member 9
(CARD9) deficiency [97], or patients who receive biological therapies, such as tumor necrosis factor-α
inhibitors, and new small molecule kinase inhibitors, such as ibrutinib [98]. Clinical presentations
of IA in many of these patient groups are atypical and diagnosis remains challenging. Early and
targeted systemic antifungal treatment remains the most important predictive factor for successful
outcome in immunocompromised individuals, and recent guidelines recommend both voriconazole
and isavuconazole for primary treatment of IA. Few studies evaluated treatment options for CPA,
where long-term oral itraconazole or voriconazole remain the treatment of choice.
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